Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Roshini Claire Anthony, 6 days ago

Female cancer survivors who undergo fertility preservation before cancer treatment often use their stored gametes/embryos. This highlights the effectiveness of pre-cancer fertility preservation, according to a study presented at ESHRE 2020.

 

Improving survival with CDK4/6 inhibitors in postmenopausal HR+/HER2-metastatic breast cancer patients

Rachel Soon
Medical Writer
28 Feb 2018

Since the US FDA’s approval of the first cyclin-dependent kinase (CDK) inhibitor in February 2015, the molecules continue to be put to the test as part of the treatment regimen for patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC), whether as first- or second-line therapies. While overall survival data has yet to mature from clinical trials, the intermediate results appear to support the present use of CDK 4/6 in combination with endocrine therapy in delaying further onset of the disease.

Recent updates on CDK 4/6 trials were reviewed and discussed at the recent European Society for Medical Oncology (ESMO) Congress 2017 in Madrid, Spain, by Dr Alessandra Gennari, medical director of the Division of Medical Oncology of Galliera Hospital, Genoa, Italy; as well as at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting in Chicago, USA, by Dr Ingrid A. Mayer, clinical director of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center, Nashville, USA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Roshini Claire Anthony, 6 days ago

Female cancer survivors who undergo fertility preservation before cancer treatment often use their stored gametes/embryos. This highlights the effectiveness of pre-cancer fertility preservation, according to a study presented at ESHRE 2020.